#Rare Disease

Lead report

Ionis Licenses Zilganerse to Recordati Outside U.S. in Biotech Deal

Ionis Pharmaceuticals has signed an exclusive licensing agreement with Recordati for its rare disease drug Zilganerse, covering markets outside the United States. The deal highlights strategic risk-sharing and commercial expansion in the biopharma sector.